Trial intelligence / Profile preview

Phase 3 extension study of ritlecitinib in adults and adolescents with nonsegmental vitiligo

CTR20241302Phase 3Completed

Sponsor
Pfizer
Start
Jun 2024
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of ritlecitinib tosilate in nonsegmental vitiligo, sponsored by Pfizer. Started Jun 2024; status: completed.

02

Drugs

ritlecitinib tosilate
03

Conditions

nonsegmental vitiligo

Beyond the preview

Go deeper on CTR20241302.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20241302.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call